Navigation Links
Drug Discovery in Rare Diseases
Date:9/20/2012

NEW YORK, Sept. 20, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Drug Discovery in Rare Diseases

http://www.reportlinker.com/p0968548/Drug-Discovery-in-Rare-Diseases.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

 

In comparison with major diseases, the targeting of rare diseases poses many different challenges, necessitating consideration of bespoke R&D strategies for drug discovery efforts to be successful. This report examines the role that low disease prevalence plays in determining the most suitable R&D path.Understand the growing interest in developing new treatments for rare diseases, and why low patient numbers do not preclude commercial viability.Review the regulatory environment governing the development of orphan drugs in different countries.Identify the key challenges that are presented by low patient prevalences.Assess how the research strategy chosen can be influenced by the disease prevalence.Compare the scenarios in which repurposing of existing drugs offers advantages over the development of novel drugs, and vice versa.Approximately 7,000 rare diseases have been identified, but only a very small proportion of these are currently well treated. Orphans represent a greater proportion of all new BLAs than they do of NMEs submitted as NDAs. Most orphan approvals are not first approvals of new drugs but are new orphan indications for previously approved drugs.It is possible to obtain orphan drug designation for conditions with a total prevalence greater than that defined by legislation, but only if medically justifiable subsets can be defined with a lower (overall) prevalence. Pediatric subsets are most commonly used.In the development of new treatments for rare diseases it is less critical to seek to optimize the pharmacokinetic properties of candidates than is the case for common chronic diseases, with parenteral delivery or frequent oral dosing being much more acceptable provided that efficacy is achieved.What impact on R&D strategy does disease prevalence have on moving from rare through very rare to ultra rare diseases?Can more than one drug be a commercial success for treating rare indications, and how do drug regulators view the question of drug similarity?What are the best ways of identifying patients for recruitment into clinical trials for drugs designed to treat rare diseases?What are the requirements for a clinical candidate to treat a rare disease?What factors determine whether a small-molecule or biologic strategy is most suitable when targeting a rare disease?

 

 

 

EXECUTIVE SUMMARY•Key findings

 

The growing interest in rare diseases•Summary

•Introduction

•What is a rare disease?

•Why target rare diseases?

 

Characterization of rare diseases•Summary

•Overview

•Rare diseases

•Very rare diseases

•Ultra rare diseases

•Useful resources

 

Orphan drug status•Summary

•Introduction

•Legislative distinctions - US

- Europe

- Japan

- Other markets

 

•Tax benefits

•Patient population subsetting

•Similarity

•Summary of key considerations

 

Choosing rare diseases to target•Summary

•Introduction

•Key issues

•Commercial potential - Prevalence

- Geographic distribution

- Disease understanding

- Available experts

- Current treatments

- What is similar?

 

•Conclusion

 

Preclinical development•Summary

•Introduction

•Screen or repurpose? - Repurposed

- Directed approaches

- Taking advantage of orphan drug status

 

•Other issues - Small molecule or biological?

- Biological test models

- Requirements of a clinical candidate

 

•Conclusions

 

Clinical issues•Summary

•Introduction

•Clinical trial design

•Access to patients - Geographic distribution

- Identifying patients

 

•Conclusions

 

Commercial considerations•Summary

•Introduction

•Identifying commercially promising opportunities - Prevalence

- Current treatments

- Competitive position

 

•Case studies - (Untitled sub-section)

- Gaucher disease

 

•Conclusions

 

Conclusions•Summary

•Introduction

•Checklist to consider

•Corporate strategies

•Conclusions

 

Appendix•Scope

•Methodology

•Glossary/abbreviations

•Bibliography/references

 

 

TABLES

•Table: Timeline of international orphan drug legislation, 1983–2008

•Table: Comparison of orphan drug legislation in the US, Europe, and Japan

•Table: The FDA's definitions of similarity

 

 

FIGURES

•Figure: US FDA orphan approvals, 2001–11 (part 1)

•Figure: US FDA orphan approvals, 2001–11 (part 2)

•Figure: Rare diseases, medical need, and disease prevalence

•Figure: Distribution of US orphan drug approvals by disease prevalence (to 2010)

•Figure: European orphan drug approvals by disease prevalence (to 2010)

•Figure: Exploiting knowledge resources for rare disease research

•Figure: The organizational relationships within the EMA pertaining to orphan drugs

•Figure: Schematic relationship between rare disease prevalence and commercial returns

•Figure: Identifying suitable patients for clinical studies

•Figure: The influence of prevalence on research strategy

•Figure: Current exploitation of rare disease space

•Figure: "Similar" approved BCR-ABL inhibitors with orphan drug status

•Figure: Similar approved endothelin receptor antagonists with orphan drug status

•Figure: Selecting a rare disease to target

•Figure: Alternative strategies to identifying new treatments for rare diseases

•Figure: Strategic pathways for identifying development candidates

•Figure: Comparison of duration and size of clinical studies in developing drugs to treat major diseases (a), and rare diseases (b)

•Figure: Number of participants in European orphan drug clinical trials

•Figure: Comparing commercial opportunities

•Figure: Strategic options for developing drugs for already targeted rare diseases

•Figure: Different approaches to treating cystic fibrosis

•Figure: GlaxoSmithKline and Pfizer; exploiting internal and external resources in rare disease research

 

 

 

Companies Mentioned

Amlin plc, GlaxoSmithKline Plc, Hutchison 3G UK Limited, Recordati S.p.A., Sanofi, WPP Group plc

 

 

 

To order this report:

Drug_Discovery_and_Development Industry: Drug Discovery in Rare Diseases

 

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ESTEVE Fosters R & D by Transferring its Center for Drug Discovery to the Science Park of Barcelona (PCB)
2. Initiating Rare Disease Drug Discovery Projects
3. Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
4. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
5. Drug Discovery Technologies, BCC Research
6. Antigen Discovery Inc. Awarded Phase I SBIR Grant to Develop a Fully Integrated Microfluidic Point of Care Diagnostic Device
7. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
8. Zenobia Therapeutics Announce A Partnership With The Alzheimers Drug Discovery Foundation
9. Antigen Discovery, Inc. Awarded Phase II SBIR Grant to Identify Biomarkers Associated with Protection against Malaria
10. Omeros Announces Discovery in MASP-2 Program
11. Discovery Labs Receives US Patent for Method to Promote Mucus Clearance with Pulmonary Surfactant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)...   ZirMed Inc ., a recognized leader in cloud-based ... has been ranked #1 by its users for the seventh ... User Survey. ZirMed was recognized as the top-ranked end-to-end revenue ... centers over 200 beds and holds one of the longest ... history. ...
Breaking Medicine Technology:
(Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... ... 2017 , ... Lori R. Somekh, founder of the Law Office of ... elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain ... to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
Breaking Medicine News(10 mins):